Is CAR-T therapy available in China for foreign patients?

Yes. China has 4 NMPA-approved CAR-T products as of 2024 covering relapsed/refractory B-cell lymphomas, acute lymphoblastic leukaemia (ALL), and multiple myeloma. Treatment is delivered at Class A hospitals with NMPA-licensed cellular therapy laboratories. Total all-in cost runs $60,000–$140,000 — roughly one-third of US pricing.

What CAR-T products are approved in China?

Four NMPA-approved products: (1) Yikaida 奕凯达 (axicabtagene ciloleucel — Yescarta licensed via Fosun Kite); (2) Carteyva 倍诺达 (relmacabtagene autoleucel — JW Therapeutics, China-developed); (3) Fukerui 福可苏 (equecabtagene autoleucel — IASO Bio); (4) Yuanruida 源瑞达 (zevorcabtagene autoleucel — multiple myeloma indication, CARsgen). Indications and dosing differ — your oncologist will recommend based on disease and prior treatment lines.

What conditions does CAR-T treat?

Currently approved indications in China: relapsed/refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell ALL (acute lymphoblastic leukaemia), and relapsed/refractory multiple myeloma. Solid tumour CAR-T programs are in trials but not yet approved. CAR-T is a third- or fourth-line treatment after standard chemotherapy has failed.

What are the response rates?

Published Chinese real-world data closely match US registration trial data: ~80% overall response rate and ~50–55% complete response in DLBCL; ~90% in pediatric/young adult B-ALL; ~70–80% in multiple myeloma. Long-term remission (3+ years) occurs in ~40% of DLBCL responders. Outcomes depend on disease bulk, prior treatment lines, and toxicity management.

How does CAR-T treatment work logistically?

Six steps: (1) eligibility assessment + bridging chemotherapy if needed; (2) leukapheresis (~4 hours) to collect T-cells; (3) cells shipped to manufacturing facility; (4) genetic engineering and expansion (10–14 days); (5) lymphodepleting chemotherapy 3–5 days before infusion; (6) CAR-T infusion + 2–4 week inpatient observation for cytokine release syndrome (CRS) and neurotoxicity. Total stay: ~6 weeks.

How much does CAR-T cost in China vs the US?

China all-in cost (drug + hospitalisation + bridging therapy + 4 weeks observation): $60,000–$140,000 depending on product and centre. US list prices: Yescarta $373,000, Kymriah $475,000, Carvykti $465,000 — plus $100,000+ hospitalisation. China pricing reflects domestic manufacturing, lower facility costs, and competitive multi-product market.

What hospitals offer CAR-T in China?

Class A centres with NMPA-licensed cellular therapy facilities: Beijing 301 Hospital (PLA General Hospital), Renji Hospital Shanghai, Ruijin Hospital Shanghai, Peking Union Medical College Hospital, Tianjin Cancer Hospital, Sun Yat-sen University Cancer Center Guangzhou. Each centre has its own product partnerships — your case is assigned based on disease and product compatibility.

Oncology · CAR-T cellular immunotherapy

CAR-T therapy in China,
at one-third the cost.

4 NMPA-approved products. Class A hospital cellular therapy programs. Real-world response rates matching US registration trials. All-in pricing $60–140k vs $400k+ in the US.

Check eligibility Cancer hub

Approved products

Four NMPA-approved CAR-T products.

Lymphoma

Yikaida 奕凯达

Axicabtagene ciloleucel (Yescarta licensed via Fosun Kite). DLBCL, follicular, mantle cell. The most internationally recognised brand in China.

All-in: $120–140k

Lymphoma · China-developed

Carteyva 倍诺达

Relmacabtagene autoleucel (JW Therapeutics). Comparable efficacy to Yescarta in head-to-head Chinese RWE data, ~30% lower price.

All-in: $80–110k

Multiple myeloma

Fukerui 福可苏

Equecabtagene autoleucel (IASO Bio). BCMA-targeted CAR-T for r/r multiple myeloma. ~70% ORR in registration trial.

All-in: $100–130k

Multiple myeloma

Yuanruida 源瑞达

Zevorcabtagene autoleucel (CARsgen). Second-generation BCMA CAR-T. Approved 2023 with strong response data.

All-in: $90–120k

Source: NMPA approval registry, manufacturer disclosures, Chinese RWE publications 2023–2024.

FAQ

CAR-T, in plain language.

Is CAR-T therapy available in China for foreign patients?: Yes. China has 4 NMPA-approved CAR-T products as of 2024 covering relapsed/refractory B-cell lymphomas, acute lymphoblastic leukaemia (ALL), and multiple myeloma. Treatment is delivered at Class A hospitals with NMPA-licensed cellular therapy laboratories. Total all-in cost runs $60,000–$140,000 — roughly one-third of US pricing.
What CAR-T products are approved in China?: Four NMPA-approved products: (1) Yikaida 奕凯达 (axicabtagene ciloleucel — Yescarta licensed via Fosun Kite); (2) Carteyva 倍诺达 (relmacabtagene autoleucel — JW Therapeutics, China-developed); (3) Fukerui 福可苏 (equecabtagene autoleucel — IASO Bio); (4) Yuanruida 源瑞达 (zevorcabtagene autoleucel — multiple myeloma indication, CARsgen). Indications and dosing differ — your oncologist will recommend based on disease and prior treatment lines.
What conditions does CAR-T treat?: Currently approved indications in China: relapsed/refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell ALL (acute lymphoblastic leukaemia), and relapsed/refractory multiple myeloma. Solid tumour CAR-T programs are in trials but not yet approved. CAR-T is a third- or fourth-line treatment after standard chemotherapy has failed.
What are the response rates?: Published Chinese real-world data closely match US registration trial data: ~80% overall response rate and ~50–55% complete response in DLBCL; ~90% in pediatric/young adult B-ALL; ~70–80% in multiple myeloma. Long-term remission (3+ years) occurs in ~40% of DLBCL responders. Outcomes depend on disease bulk, prior treatment lines, and toxicity management.
How does CAR-T treatment work logistically?: Six steps: (1) eligibility assessment + bridging chemotherapy if needed; (2) leukapheresis (~4 hours) to collect T-cells; (3) cells shipped to manufacturing facility; (4) genetic engineering and expansion (10–14 days); (5) lymphodepleting chemotherapy 3–5 days before infusion; (6) CAR-T infusion + 2–4 week inpatient observation for cytokine release syndrome (CRS) and neurotoxicity. Total stay: ~6 weeks.
How much does CAR-T cost in China vs the US?: China all-in cost (drug + hospitalisation + bridging therapy + 4 weeks observation): $60,000–$140,000 depending on product and centre. US list prices: Yescarta $373,000, Kymriah $475,000, Carvykti $465,000 — plus $100,000+ hospitalisation. China pricing reflects domestic manufacturing, lower facility costs, and competitive multi-product market.
What hospitals offer CAR-T in China?: Class A centres with NMPA-licensed cellular therapy facilities: Beijing 301 Hospital (PLA General Hospital), Renji Hospital Shanghai, Ruijin Hospital Shanghai, Peking Union Medical College Hospital, Tianjin Cancer Hospital, Sun Yat-sen University Cancer Center Guangzhou. Each centre has its own product partnerships — your case is assigned based on disease and product compatibility.

Eligibility check
in 7 business days.

Submit pathology, prior treatment history, and current imaging. A senior haematology-oncologist will confirm CAR-T candidacy and recommend product and centre.

Submit case Second-opinion service

CAR-T therapy in China,at one-third the cost.